Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin versus sitagliptin added to metformin for type 2 diabetes mellitus with non-alcoholic steatohepatitis
ACTRN12624000039583Phase 4Not yet recruiting
- Sponsor
- Lady Reading Hospital
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes mellitus (T2DM) comparing Dapagliflozin + metformin with Sitagliptin + metformin (2 arms). Primary endpoint: Change in alanine transaminase. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
dapagliflozinsitagliptinmetformin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ACTRN12624000039583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000039583.